LSLynne Warner Stevenson

Lynne Warner Stevenson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lynne Warner Stevenson has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Atrial Fibrillation in Genotyped Dilated Cardiomyopathy: Epidemiology, Risk Factors, and Outcomes: Insights From the SHaRe Registry

    by Iswaree D. Balakrishnan, Astrid B.M. Heymans, Brian Claggett, Garrick C. Stewart, Christine E. Seidman, Sophie L.V.M. Stroeks, Nina J. Beelen, Max F.G.H.M. Venner, Anjali T. Owens, Sharlene M. Day, et al.

    BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia in dilated cardiomyopathy (DCM) and is associated with adverse outcomes. However, the genetic determinants of AF risk and its prognostic significance across genotyped DCM subtypes remain unknown. METHODS: In this observational cohort study, we analyzed 3117 genotyped patients with DCM from the SHaRe (Sarcomeric Human Cardiomyopathy Registry). AF prevalence, incidence, and clinical characteristics were assessed by genotype. Patients were classified as genotype-positive [G(+)] if they had a pathogenic or likely pathogenic variant in a DCM-associated gene, and genotype-negative [G(−)] if genetic testing was negative. Factors associated with incident AF were evaluated using Cox regression. AF was modeled as a time-dependent variable to evaluate associations with clinical outcomes. RESULTS: Among 3117 genotyped patients with DCM (mean age, 48±15 years; 39% were female; and 35% were G[+]), 12.3% (n=384) had prevalent AF. Of 2491 patients without prevalent AF and with follow-up, 312 (12.5%) developed AF during a median of 4.5 years (interquartile range, 1.6–9.0). Among 2851 patients with follow-up, cumulative AF prevalence was 23.6%. LMNA had the highest AF incidence (7.6/100 patient-years) and cumulative AF prevalence (56.7%) and was the only genotype independently associated with incident AF compared with that in G(−) patients (hazard ratio, 5.52 [95% CI, 3.84–7.95]; P TTN had an AF incidence of 2.1 per 100 patient-years and cumulative AF prevalence of 24.4%, comparable to that in G(−) patients. Older age, male sex, and prior heart failure hospitalization were also independently associated with incident AF. AF was independently associated with a higher risk of the composite clinical outcome (hazard ratio, 1.58 [95% CI, 1.29–1.94]; P LMNA was associated with an increased risk of incident AF. AF onset was independently associated with adverse outcomes, supporting genotype-guided AF surveillance and management in DCM.

  • Prevalence of Clinically Recognized Phenotypes in Advanced Heart Failure

    by Kyle G. Steiger, Jill M. Killian, Lynne W. Stevenson, Margaret Redfield, Shannon M. Dunlay

  • Staging a comeback for digitalis

    by Lynne W Stevenson, Katherine T Murray


  • Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure

    by Deepak K. Gupta, Lynne W. Stevenson, Erica M. Garner, Christopher Maulion, Hui Nian, Patricia R. Wright, Adina F. Turcu, Shouzou Wei, Nancy J. Brown

    BACKGROUND: Symptomatic hypotension can limit sacubitril/valsartan therapy. Neprilysin inhibition may augment vasodilators, such as bradykinin. We hypothesized that bradykinin contributes to blood pressure (BP) lowering with sacubitril/valsartan in stable ambulatory patients with heart failure and reduced ejection fraction P =0.013). Icatibant also decreased renal plasma flow and increased renal vascular resistance after chronic dosing, without affecting heart rate, urine volume, urine sodium, cGMP/creatinine, or natriuretic peptides. CONCLUSIONS: BP lowering with sacubitril/valsartan occurs with both acute and chronic dosing. ANP (1–28) appears to mediate the initial BP reduction, whereas bradykinin contributes to BP lowering after dosing during chronic therapy. Clarifying these mechanisms may inform clinical management to optimize the benefit of this important heart failure and reduced ejection fraction therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04113109.


  • Open Access

    iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025

    by Vijay Chopra, Muhammad Shahzeb Khan, Magdy Abdelhamid, William T. Abraham, Offer Amir, Stefan D. Anker, John J. Atherton, Fernando Bacal, Ralph Stephen von Bardeleben, Dulce Brito, et al.


  • Open Access

    Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure

    by Michael R. Zile, William T. Abraham, Lynne W. Stevenson, Maria Rosa Costanzo, Christiane E. Angermann, Mandeep R. Mehra, Akshay S. Desai, Anique Ducharme, Nessa Johnson, John Henderson, et al.

    BACKGROUND: Hemodynamically guided management of patients with chronic heart failure (HF), using a remote, ambulatory pulmonary artery (PA) pressure monitor, has been shown to reduce mortality and morbidity. These improved outcomes were associated with a reduction in PA pressure. However, several pivotal questions remain unanswered: do systolic, diastolic, or mean PA pressures each predict all-cause mortality? Do PA pressures predict mortality across the ejection fraction (EF) spectrum? Do increases or decreases in PA pressure over time predict increases or decreases in mortality? METHODS: Retrospective analyses of data from CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients; n=550), GUIDE-HF (Hemodynamic-GUIDEed management of Heart Failure; n=2358), US PAS (CardioMEMS HF System Post Approval Study; n=1200), and MEMS-HF (CardioMEMS Monitoring Study for Heart Failure; n=234) were performed, including all enrolled patients regardless of treatment assignments (Total N=4342). PA systolic, PA diastolic, and PA mean pressures were examined in patients with HF and reduced EF (P 2 mm Hg compared with no change predicted a 14.7% decrease and 26.7% increase in mortality, respectively ( P =0.0237). PA systolic and PA mean pressures in both HF with reduced EF and HF with preserved EF patients, for both baseline and change from baseline to 6 months, were also predictive of all-cause mortality. CONCLUSIONS: Baseline PAP (systolic, diastolic, and mean) and change in PAP (systolic, diastolic, and mean) from baseline to 6 months were independent predictors of 2-year mortality in patients with chronic HF in both preserved and reduced EF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: CHAMPION, NCT00531661; GUIDE-HF, NCT03387813; USPAS, NCT02279888; MEMS-HF, NCT02693691.


  • Wet and Sent Home From Heart Failure Hospitalization

    by Sean P. Collins, Hasan K. Siddiqi, Lynne Warner Stevenson


  • Open Access

    Correlates of Plasma NT‐proBNP/Cyclic GMP Ratio in Heart Failure With Preserved Ejection Fraction: An Analysis of the RELAX Trial

    by Leonard Chiu, Vineet Agrawal, David Armstrong, Evan Brittain, Sheila Collins, Anna R. Hemnes, Joseph A. Hill, JoAnn Lindenfeld, Sanjiv J. Shah, Lynne W. Stevenson, et al.

    Background: Phosphodiesterases degrade cyclic GMP (cGMP), the second messenger that mediates the cardioprotective effects of natriuretic peptides. High natriuretic peptide/cGMP ratio may reflect, in part, phosphodiesterase activity. Correlates of natriuretic peptide/cGMP in patients with heart failure with preserved ejection fraction are not well understood. Among patients with heart failure with preserved ejection fraction in the RELAX (Phosphodiesterase‐5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction) trial, we examined (1) cross‐sectional correlates of circulating NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide)/cGMP ratio, (2) whether selective phosphodiesterase‐5 inhibition by sildenafil changed the ratio, and (3) whether the effect of sildenafil on 24‐week outcomes varied by baseline ratio. Methods and Results: In 212 subjects, NT‐proBNP/cGMP ratio was calculated at randomization and 24 weeks. Correlates of the ratio and its change were examined in multivariable proportional odds models. Whether baseline ratio modified the sildenafil effect on outcomes was examined by interaction terms. Higher NT‐proBNP/cGMP ratio was associated with greater left ventricular mass and troponin, the presence of atrial fibrillation, and lower estimated glomerular filtration rate and peak oxygen consumption. Compared with placebo, sildenafil did not alter the ratio from baseline to 24 weeks ( P =0.17). The effect of sildenafil on 24‐week change in peak oxygen consumption, left ventricular mass, or clinical composite outcome was not modified by baseline NT‐proBNP/cGMP ratio ( P ‐interaction >0.30 for all). Conclusions: Among patients with heart failure with preserved ejection fraction, higher NT‐proBNP/cGMP ratio associated with an adverse cardiorenal phenotype, which was not improved by selective phosphodiesterase‐5 inhibition. Other phosphodiesterases may be greater contributors than phosphodiesterase‐5 to the adverse phenotype associated with a high natriuretic peptide/cGMP ratio in HFpEF. Registration Information: clinicaltrials.gov . Identifier: NCT00763867 .